Matrix Metalloproteinases in Kidney Homeostasis and Diseases: an Update

Overview

Journal Am J Physiol Renal Physiol

Publisher American Physiological Society

Specialties Nephrology
Physiology

Date 2024 Oct 3

PMID 39361724

Authors

Roderick J Tan

Youhua Liu

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases with important roles in kidney homeostasis and pathology. While capable of collectively degrading each component of the extracellular matrix, MMPs also degrade nonmatrix substrates to regulate inflammation, epithelial plasticity, proliferation, apoptosis, and angiogenesis. More recently, intriguing mechanisms that directly alter podocyte biology have been described. There is now irrefutable evidence for MMP dysregulation in many types of kidney disease including acute kidney injury, diabetic and hypertensive nephropathy, polycystic kidney disease, and Alport syndrome. This updated review will detail the complex biology of MMPs in kidney disease.

Citing Articles

Urine Matrix Metalloproteinase-7 (MMP-7) Versus Urine Albumin-to-Creatinine Ratio (ACR) as Predictors of Renal Dysfunction: A Decision Curve Analysis.

Sarangi R, Sahu D, Rout N, Padarabinda Tripathy K, Patra S, Bahinipati J Cureus. 2025; 17(1):e78275.

PMID: 40026998 PMC: 11872044. DOI: 10.7759/cureus.78275.

References

Elster E, Hawksworth J, Cheng O, Leeser D, Ring M, Tadaki D . Probabilistic (Bayesian) modeling of gene expression in transplant glomerulopathy. J Mol Diagn. 2010; 12(5):653-63. PMC: 2928430. DOI: 10.2353/jmoldx.2010.090101. View

Tveita A, Rekvig O, Zykova S . Increased glomerular matrix metalloproteinase activity in murine lupus nephritis. Kidney Int. 2008; 74(9):1150-8. DOI: 10.1038/ki.2008.308. View

Nakamura T, Ushiyama C, Suzuki S, Ebihara I, Shimada N, Koide H . Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol. 2000; 20(1):32-6. DOI: 10.1159/000013552. View

Thrailkill K, Bunn R, Moreau C, Cockrell G, Simpson P, Coleman H . Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care. 2007; 30(9):2321-6. PMC: 2239013. DOI: 10.2337/dc07-0162. View

Bello-Reuss E, HOLUBEC K, Rajaraman S . Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int. 2001; 60(1):37-45. DOI: 10.1046/j.1523-1755.2001.00768.x. View

Pavkovic M, Pantano L, Gerlach C, Brutus S, Boswell S, Everley R . Multi omics analysis of fibrotic kidneys in two mouse models. Sci Data. 2019; 6(1):92. PMC: 6570759. DOI: 10.1038/s41597-019-0095-5. View

Rajagopalan S, Meng X, Ramasamy S, Harrison D, Galis Z . Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996; 98(11):2572-9. PMC: 507715. DOI: 10.1172/JCI119076. View

Hu Y, Ivashkiv L . Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J Immunol. 2006; 176(10):6022-33. DOI: 10.4049/jimmunol.176.10.6022. View

Tan R, Liu Y . Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012; 302(11):F1351-61. PMC: 3774496. DOI: 10.1152/ajprenal.00037.2012. View

10.

Tashiro K, Koyanagi I, Ohara I, Ito T, Saitoh A, Horikoshi S . Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2004; 18(3):206-10. PMC: 6807695. DOI: 10.1002/jcla.20024. View

11.

Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw S, Bell M . Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013; 17(1):R25. PMC: 4057242. DOI: 10.1186/cc12503. View

12.

Feng W, Guan Z, Ying W, Xing D, Ying K, Sanders P . Matrix metalloproteinase-9 regulates afferent arteriolar remodeling and function in hypertension-induced kidney disease. Kidney Int. 2023; 104(4):740-753. PMC: 10854403. DOI: 10.1016/j.kint.2023.06.031. View

13.

Tveita A, Rekvig O, Zykova S . Glomerular matrix metalloproteinases and their regulators in the pathogenesis of lupus nephritis. Arthritis Res Ther. 2008; 10(6):229. PMC: 2656222. DOI: 10.1186/ar2532. View

14.

Chang H, Kuo W, Hsieh Y, Yang S, Lin C, Lee M . Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients. Transl Res. 2008; 151(4):217-23. DOI: 10.1016/j.trsl.2007.12.004. View

15.

Lee S, Horbelt M, Mang H, Knipe N, Bacallao R, Sado Y . MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury. Am J Physiol Renal Physiol. 2011; 301(1):F101-9. PMC: 3129879. DOI: 10.1152/ajprenal.00445.2010. View

16.

Zhou D, Tian Y, Sun L, Zhou L, Xiao L, Tan R . Matrix Metalloproteinase-7 Is a Urinary Biomarker and Pathogenic Mediator of Kidney Fibrosis. J Am Soc Nephrol. 2016; 28(2):598-611. PMC: 5280025. DOI: 10.1681/ASN.2016030354. View

17.

Obermuller N, Morente N, Kranzlin B, Gretz N, Witzgall R . A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol. 2001; 280(3):F540-50. DOI: 10.1152/ajprenal.2001.280.3.F540. View

18.

Phillips T, Fadia M, Lea-Henry T, Smiles J, Walters G, Jiang S . MMP2 and MMP9 associate with crescentic glomerulonephritis. Clin Kidney J. 2017; 10(2):215-220. PMC: 5455255. DOI: 10.1093/ckj/sfw111. View

19.

Li S, Huang P, Yang A, Tarng D, Yang W, Lin C . Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney Int. 2014; 86(2):358-69. DOI: 10.1038/ki.2014.67. View

20.

Tomlinson M, Garcia-Morales C, Abu-Elmagd M, Wheeler G . Three matrix metalloproteinases are required in vivo for macrophage migration during embryonic development. Mech Dev. 2008; 125(11-12):1059-70. DOI: 10.1016/j.mod.2008.07.005. View